Earnings results for Vertex Pharmaceuticals (NASDAQ:VRTX)
Vertex Pharmaceuticals Incorporated is expected* to report earnings on 04/29/2021 after market close. The report will be for the fiscal Quarter ending Mar 2021. According to Zacks Investment Research, based on 8 analysts’ forecasts, the consensus EPS forecast for the quarter is $2.38. The reported EPS for the same quarter last year was $2.21.
Vertex Pharmaceuticals last announced its earnings results on January 31st, 2021. The pharmaceutical company reported $2.51 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.59 by $0.08. The firm earned $1.63 billion during the quarter, compared to analyst estimates of $1.58 billion. Vertex Pharmaceuticals has generated $4.29 earnings per share over the last year and currently has a price-to-earnings ratio of 27.0. Vertex Pharmaceuticals has confirmed that its next quarterly earnings report will be published on Thursday, April 29th, 2021. Vertex Pharmaceuticals will be holding an earnings conference call on Thursday, April 29th. Interested parties can register for or listen to the call using this link.
Analyst Opinion on Vertex Pharmaceuticals (NASDAQ:VRTX)
26 Wall Street analysts have issued ratings and price targets for Vertex Pharmaceuticals in the last 12 months. Their average twelve-month price target is $293.21, predicting that the stock has a possible upside of 37.35%. The high price target for VRTX is $347.00 and the low price target for VRTX is $250.00. There are currently 4 hold ratings, 21 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of “Buy.”
Vertex Pharmaceuticals has received a consensus rating of Buy. The company’s average rating score is 2.88, and is based on 21 buy ratings, 4 hold ratings, and no sell ratings. According to analysts’ consensus price target of $293.21, Vertex Pharmaceuticals has a forecasted upside of 37.3% from its current price of $213.48. Vertex Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.
Dividend Strength: Vertex Pharmaceuticals (NASDAQ:VRTX)
Vertex Pharmaceuticals does not currently pay a dividend. Vertex Pharmaceuticals does not have a long track record of dividend growth.
Insiders buying/selling: Vertex Pharmaceuticals (NASDAQ:VRTX)
In the past three months, Vertex Pharmaceuticals insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,533,052.00 in company stock. Only 0.70% of the stock of Vertex Pharmaceuticals is held by insiders. 92.17% of the stock of Vertex Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Earnings and Valuation of Vertex Pharmaceuticals (NASDAQ:VRTX
Earnings for Vertex Pharmaceuticals are expected to grow by 9.29% in the coming year, from $8.50 to $9.29 per share. The P/E ratio of Vertex Pharmaceuticals is 26.95, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.88. The P/E ratio of Vertex Pharmaceuticals is 26.95, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 46.05. Vertex Pharmaceuticals has a PEG Ratio of 1.25. PEG Ratios above 1 indicate that a company could be overvalued. Vertex Pharmaceuticals has a P/B Ratio of 9.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
More latest stories: here